Company intelligence / Profile preview

Neurokin

Ownership: Private
Development stage: Phase 2

Overview

Neurokin was a French biotech spin-out from INSERM (founded in Marseille in 2003) dedicated to developing neuroprotective drugs for acute neurological disorders. Its lead candidate, NK-102, showed proof-of-concept efficacy in animal models of stroke and epilepsy by inhibiting neuronal apoptosis and glial cell proliferation. The company secured €1.5M public funding circa late-2010 to support preclinical work with academic collaborators at INSERM units; the goal was to enter clinical development around or after ~2012. There is no recent information indicating ongoing activity or further clinical progress.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

NK-102

Unknown

Beyond the preview

Go deeper on Neurokin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurokin.